Update on access to Zoladex treatment

Breast Cancer Network Australia is aware of AstraZeneca’s decision to discontinue the Zoladex (goserelin) 3.6mg implant in Australia from 1 November 2026. We understand this news may be unsettling for people currently using this treatment, and we want to acknowledge that we share your concerns.

Over the last week, BCNA has undertaken coordinated advocacy with consumers, clinicians and other key stakeholders to raise concerns directly with AstraZeneca on behalf of people with breast cancer impacted by this medication change. As a result, we are pleased to inform you that a number of options will be made available to support people with breast cancer:

• Eligible patients who do not have suitable alternative treatment options will be able to access Zoladex 3.6mg free of charge through a new access program, expected to begin from 1 November and run initially for six months.
• AstraZeneca has submitted an application to make the three-monthly Zoladex 10.8mg implant available on the Pharmaceutical Benefits Scheme (PBS) for hormone-receptor positive breast cancer patients. 

BCNA is continuing to work closely with clinicians, consumers and key stakeholders to help achieve a longer-term solution and minimise disruption for people affected by breast cancer.

You can also contact our Helpline if you need support or would like to learn more about our advocacy on this issue.